TroFuse-033 trial: what clinicians have said so far
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- NCT06952504 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on TroFuse-033 (sacituzumab tirumotecan plus pembrolizumab in mismatch repair-proficient endometrial cancer, first-line maintenance) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TroFuse-033 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 8 YouTube videos, typically up to 35 once built | |
| 3 podcast episodes, typically up to 13 once built | |
| 1 post on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Endometrial Cancer
- Interventions
- Pembrolizumab; Carboplatin; Paclitaxel; Docetaxel; Sacituzumab Tirumotecan; Cisplatin
- Arms
- Maintenance Treatment Arm A: Pembrolizumab + Sacituzumab Tirumotecan · Experimental
- Maintenance Treatment Arm B: Pembrolizumab Monotherapy · Active comparator
- Subsequent Treatment Arm A: Pembrolizumab + Sacituzumab Tirumotecan · Experimental
- Subsequent Treatment Arm B: Sacituzumab Tirumotecan Monotherapy · Active comparator
- Enrollment
- 1,123 (estimated)
- Primary outcomes
- Maintenance Treatment: Progression-Free Survival (PFS)
- Maintenance Treatment: Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- May 22, 2025
- Primary completion
- May 24, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT06952504 · updated Nov 10, 2026